Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Feb;85(2):165-174.
doi: 10.1002/pros.24813. Epub 2024 Oct 17.

Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study

Takafumi Yanagisawa  1 , Wataru Fukuokaya  1 , Shingo Hatakeyama  2 , Shintaro Narita  3 , Katsuki Muramoto  1 , Kouta Katsumi  1 , Hidetsugu Takahashi  1 , Fumihiko Urabe  1 , Keiichiro Mori  1 , Kojiro Tashiro  1 , Kosuke Iwatani  1 , Tatsuya Shimomura  1 , Tomonori Habuchi  2 , Takahiro Kimura  1
Affiliations
Comparative Study

Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study

Takafumi Yanagisawa et al. Prostate. 2025 Feb.

Abstract

Purpose: We aimed to assess the differential efficacy and safety of androgen receptor pathway inhibitors (ARPI), such as abiraterone, enzalutamide, and apalutamide, in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in a real-world practice setting.

Methods: We retrospectively reviewed the records of consequent 668 patients with mHSPC treated with ARPI plus androgen deprivation therapy between September 2015 and December 2023. Based on the LATITUDE criteria, the comparison among abiraterone, enzalutamide, and apalutamide was exclusively conducted in high-risk patients. Prostate-specific antigen (PSA) responses such as the achievement of 95% and 99% PSA decline, overall survival (OS), cancer-specific survival (CSS), time to castration-resistant prostate cancer (CRPC), and the incidence of adverse events (AEs) were compared. All two-group comparisons relied on propensity score matching (PSM) to minimize the effect on possible confounders.

Results: In total, 297 patients with high-risk mHSPC treated with abiraterone, 127 with enzalutamide, and 142 with apalutamide were compared. There were no differences in time to CRPC (p = 0.13), OS (p = 0.7), and CSS (p = 0.5) among the three ARPIs. No differences were observed in the achievement rates for 95% PSA decline at 3 months among the three ARPIs, while abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). The aforementioned oncologic outcomes were sustained even when performing PSM analyzes. Although skin rash for APA (34%) was the highest incidence of AEs, there were no differences in the rates of severe AEs across the three ARPIs. Enzalutamide resulted in the lowest treatment discontinuation rates (10%) other than disease progression compared to the other regimens.

Conclusions: Abiraterone, enzalutamide, and apalutamide have comparable oncologic outcomes in terms of OS, CSS, and time to CRPC in patients with high-risk mHSPC. Our data on differential treatment discontinuation rates, PSA response, and AE profiles can help guide clinical decision-making.

Keywords: abiraterone; androgen receptor pathway inhibitors; apalutamide; enzalutamide; metastatic hormone‐sensitive prostate cancer.

PubMed Disclaimer

References

REFERENCES

    1. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone‐sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974‐2986.
    1. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration‐sensitive prostate cancer. N Engl J Med. 2019;381(1):13‐24.
    1. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first‐line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121‐131.
    1. Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high‐risk metastatic castration‐sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double‐blind, phase 3 trial. Lancet Oncol. 2019;20(5):686‐700.
    1. Hussain M, Tombal B, Saad F, et al. Darolutamide plus androgen‐deprivation therapy and docetaxel in metastatic hormone‐sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol. 2023;41(20):3595‐3607.

MeSH terms

LinkOut - more resources